Log In
BCIQ
Print this Print this
 

LAPS-GCSF, eflapegrastim (HM10460A, SPI-2012)

  Manage Alerts
Collapse Summary General Information
Company Hanmi Pharmaceutical Co. Ltd.
DescriptionLong-acting G-CSF analog
Molecular Target Granulocyte colony-stimulating factor (G-CSF) receptor (CSF3R) (CD114)
Mechanism of ActionGranulocyte colony stimulating factor (G-CSF) receptor (CD114) agonist
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase III
Standard IndicationNeutropenia
Indication DetailsTreat chemotherapy-induced neutropenia; Treat neutropenia
Regulatory Designation
PartnerSpectrum Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$239.0M

$1.0M

$238.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/31/2012

$239.0M

$1.0M

$238.0M

Get a free BioCentury trial today